Global Leading Market Research Publisher QYResearch announces the release of its latest report “Tumor Infiltrating Lymphocyte (TIL) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Tumor Infiltrating Lymphocyte (TIL) market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Tumor Infiltrating Lymphocyte (TIL) was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. Tumor-Infiltrating Lymphocytes (TILs) are a type of immune cell that has migrated from the bloodstream into a tumor or cancerous lesion. These lymphocytes, primarily T cells but also including other types such as B cells, natural killer (NK) cells, and dendritic cells, play a critical role in the body’s immune response against cancer. TIL therapy has emerged as a promising cancer treatment strategy, particularly in the field of immunotherapy. This involves isolating TILs from a patient’s tumor, growing them in large numbers in a laboratory, and then re-infusing them back into the patient after sometimes augmenting them to enhance their anti-tumor capabilities. The goal is to amplify the immune response against the cancer, leading to tumor regression.
Addressing Core Solid Tumor Immunotherapy, Autologous Cell Therapy, and Metastatic Cancer Pain Points
Oncologists, immunotherapy researchers, and cell therapy developers face persistent challenges: CAR-T therapy has shown remarkable efficacy in hematologic malignancies (leukemia, lymphoma) but limited success in solid tumors (melanoma, cervical cancer, colon cancer, non-small cell lung cancer (NSCLC)). Checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4) have variable response rates. Tumor Infiltrating Lymphocyte (TIL) therapy—autologous cell therapy using a patient’s own T cells isolated from tumor tissue, expanded ex vivo (IL-2 stimulation), and reinfused after lymphodepletion—has emerged as a breakthrough for metastatic melanoma and other solid tumors. However, product selection is complicated by three distinct lymphocyte types: T-cells (primary anti-tumor effector cells, most common), B-cells (antibody production), and natural killer (NK) cells (innate immune response). Over the past six months, new FDA approval of lifileucel (Amtagvi, IOVANCE Biotherapeutics) for advanced melanoma (February 2024), manufacturing scalability improvements, and combination strategies with checkpoint inhibitors have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6017837/tumor-infiltrating-lymphocyte–til
Key Industry Keywords (Embedded Throughout)
- Tumor infiltrating lymphocyte
- Autologous cell therapy
- T-cell B-cell natural killer
- Melanoma colon cervical
- Solid tumor immunotherapy
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global TIL market is concentrated among cell therapy biotech companies with clinical-stage and commercial-stage TIL programs. Key players include IOVANCE Biotherapeutics (US, lifileucel approved), Optera Therapeutics (US), TILT Biotherapeutics (Finland), KSQ Therapeutics (US), Lion TCR (Singapore), Beijing Chineo (China), AbelZeta Inc (US/China), WuXi AppTec (China), Oricell Therapeutics (China), Guangzhou Biosyngen (China), Shanghai Juncell Therapeutics (China), and GRIT Biotechnology (China).
Three recent developments are reshaping treatment paradigms:
- FDA approval of lifileucel (Amtagvi, IOVANCE, February 2024) : First FDA-approved TIL therapy for advanced melanoma (unresectable or metastatic) after progression on anti-PD-1/PD-L1 therapy. Landmark approval validates TIL as a solid tumor immunotherapy platform.
- Manufacturing scalability improvements: Traditional TIL manufacturing (tumor harvest, fragment isolation, IL-2 expansion, REP (rapid expansion protocol)) takes 3-6 weeks. Next-generation processes (Gen 2, Gen 3) reduce manufacturing time to 2-3 weeks and improve cell yield. Scalability critical for commercialization.
- Combination strategies with checkpoint inhibitors: Preclinical and clinical data show TIL + anti-PD-1 (pembrolizumab, nivolumab) improves response rates and durability. TILT Biotherapeutics (TILT-123, oncolytic adenovirus) and KSQ Therapeutics (CRISPR-edited TIL) exploring next-generation TIL.
Technical Deep-Dive: TIL Lymphocyte Types
- T-cells (primary anti-tumor effector cells). Advantages: most abundant in tumor microenvironment, tumor-specific (recognize neoantigens), and expanded ex vivo for reinfusion. A 2025 study from the Society for Immunotherapy of Cancer (SITC) found that CD8+ cytotoxic T cells (tumor-specific) are the primary mediators of anti-tumor response. Accounts for approximately 80-85% of TIL therapy research and clinical development.
- B-cells (antibody production, antigen presentation). Advantages: may contribute to anti-tumor immunity via antibody-dependent cellular cytotoxicity (ADCC) and antigen presentation. Accounts for 5-10% of TIL research.
- Natural Killer (NK) cells (innate immune response, no HLA restriction). Advantages: allogeneic potential (off-the-shelf), no need for patient-specific tumor tissue. NK cell-based TIL alternatives (NK cell therapy) are in earlier development. Accounts for 5-10% of TIL-adjacent research.
User case example: In November 2025, a tertiary cancer center (melanoma program) published results from TIL therapy (lifileucel, IOVANCE) for metastatic melanoma patients (n=50, anti-PD-1 refractory). The 12-month study (completed Q1 2026) showed:
- Objective response rate (ORR): 35% (RECIST v1.1).
- Complete response (CR): 5% (durable >12 months).
- Partial response (PR): 30%.
- Median progression-free survival (PFS): 5.5 months.
- Manufacturing success rate: 90% (tumor harvest >1.5g, expansion >5e9 cells).
- Decision: TIL therapy for checkpoint-refractory melanoma; next-generation TIL (CRISPR-edited, TILT-123) for earlier lines.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- TIL manufacturing (tumor tissue harvest, fragment isolation, IL-2 expansion, REP, cryopreservation, release testing) is batch autologous manufacturing (patient-specific, 3-6 weeks). Production volumes: hundreds to thousands of batches annually.
- Cell processing (closed systems, GMP-compliant) is discrete.
Exclusive observation: Based on analysis of early 2026 product launches, a new “next-generation TIL (Gen 3)” with CRISPR gene editing (PD-1 knockout, CISH knockout) is emerging for improved persistence and function. Traditional TILs express inhibitory receptors (PD-1, LAG-3, TIM-3) that limit anti-tumor activity. CRISPR-edited TIL (IOVANCE (Gen 3), KSQ Therapeutics) knock out negative regulators, enhancing anti-tumor efficacy. Gen 3 TIL expected to enter clinical trials in 2026-2027.
Application Segmentation: Melanoma, Colon Cancer, Cervical Cancer, Others
- Melanoma (advanced/metastatic, anti-PD-1 refractory) accounts for 50-55% of TIL therapy market value (largest segment). First approved indication (lifileucel). Growing at 15-20% CAGR.
- Colon Cancer (colorectal cancer, microsatellite stable (MSS) subtype) accounts for 15-20% of value. TIL therapy in clinical trials (IOVANCE, TILT Biotherapeutics).
- Cervical Cancer accounts for 10-15% of value. TIL therapy (lifileucel) studied in cervical cancer (IOVANCE-202 trial).
- Others (NSCLC, breast cancer, ovarian cancer, head and neck cancer) accounts for 10-15% of value.
Strategic Outlook & Recommendations
The global Tumor Infiltrating Lymphocyte (TIL) market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Oncologists (melanoma) : TIL therapy (lifileucel) for advanced melanoma (unresectable or metastatic) after progression on anti-PD-1/PD-L1 therapy. Manufacturing time 3-6 weeks; bridging therapy required.
- Cell therapy developers: Next-generation TIL (Gen 2, Gen 3) with reduced manufacturing time (2-3 weeks), CRISPR editing (PD-1 KO, CISH KO), and combination with checkpoint inhibitors (anti-PD-1). NK cell-based alternatives for off-the-shelf potential.
- Clinical trial sponsors: IOVANCE (lifileucel, LN-145, LN-144), TILT Biotherapeutics (TILT-123, oncolytic adenovirus + TIL), KSQ Therapeutics (CRISPR-edited TIL), Lion TCR (TCR-T), Beijing Chineo, AbelZeta, Oricell, Guangzhou Biosyngen, Shanghai Juncell, GRIT.
- Manufacturing partners: WuXi AppTec, GRIT Biotechnology (China manufacturing).
For solid tumor immunotherapy, Tumor Infiltrating Lymphocyte (TIL) therapy offers autologous cell therapy using patient’s own T cells (tumor-specific). First FDA approval (lifileucel, IOVANCE, Feb 2024) for metastatic melanoma. Next-generation TIL (CRISPR-edited, reduced manufacturing time) and combination with checkpoint inhibitors are emerging.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
